Author:
Metry Melissa,Krug Samuel A.,Karra Vijaya Kumari,Ekins Sean,Hoag Stephen W.,Kane Maureen A.,Fink Jeffrey C.,Polli James E.
Funder
Marilyn Shangraw
National Center for Advancing Translational Sciences
University of Maryland
National Institute of General Medical Sciences
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Organic Chemistry,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biotechnology
Reference53 articles.
1. Zhang W, Li Y, Zou P, Wu M, Zhang Z, Zhang T. The Effects of Pharmaceutical Excipients on Gastrointestinal Tract Metabolic Enzymes and Transporters-an Update. AAPS J. 2016;18(4):830–43.
2. Metry M, Polli JE. Evaluation of Excipient Risk in BCS Class I and III Biowaivers. AAPS J. 2022;24(1):20.
3. Food and Drug Administration (FDA). Guidance for Industry: M9 Biopharmaceutics Classification System-Based Biowaivers. Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). May 2021.
4. Vaithianathan S, Haidar SH, Zhang X, Jiang W, Avon C, Dowling TC, Shao C, Kane M, Hoag SW, Flasar MH, Ting TY, Polli JE. Effect of Common Excipients on the Oral Drug Absorption of Biopharmaceutics Classification System Class 3 Drugs Cimetidine and Acyclovir. J Pharm Sci. 2016;105(2):996–1005.
5. Food and Drug Administration (FDA). Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. Center for Drug Evaluation and Research (CDER). 2017
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献